Inventor

WONG PANCRAS C

US13 patents

⚠️ This page may combine multiple inventors who share the name “WONG PANCRAS C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BRISTOL MYERS SQUIBB CO

7 patents

US9688695B2Jun 27, 2017

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

BRISTOL MYERS SQUIBB CO11 citations90

US7018990B2Mar 28, 2006

Combination of a factor Xa inhibitor and clopidogrel

BRISTOL MYERS SQUIBB CO27 citations89

US10822343B2Nov 3, 2020

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation

BRISTOL MYERS SQUIBB CO4 citations83

US10428077B2Oct 1, 2019

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation

BRISTOL MYERS SQUIBB CO8 citations83

US10047103B2Aug 14, 2018

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

BRISTOL MYERS SQUIBB CO11 citations83

US9862730B2Jan 9, 2018

Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

BRISTOL MYERS SQUIBB CO5 citations70

US12084452B2Sep 10, 2024

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

BRISTOL MYERS SQUIBB CO0 citations60

DU PONT

4 patents

US5210079AMay 11, 1993

Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

DU PONT62 citations95

US5354867AOct 11, 1994

Angiotensin II receptor blocking imidazoles

DU PONT29 citations92

US5254546AOct 19, 1993

Fused aryl substituted imidazole angiotensin II receptor inhibitors

DU PONT21 citations83

US5155126AOct 13, 1992

Treatment of central nervous system disorders with pyrazole, pyrrole and triazole angiotensin-II receptor antagonists

DU PONT14 citations67

BRISTOL MYERS SQUIBB PHARMA CO

2 patents

US6346517B1Feb 12, 2002

Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders

BRISTOL MYERS SQUIBB PHARMA CO20 citations92

US6794412B1Sep 21, 2004

Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin

BRISTOL MYERS SQUIBB PHARMA CO13 citations83